Global Hepatitis B Therapeutics in Major Developed Markets 2015-2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth

Nov 12, 2015, 16:10 ET from Research and Markets

DUBLIN, Nov. 12, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth" report to their offering.

Globally, the hepatitis B therapeutics market is served moderately well by the available products, of which Baraclude and Viread are the most frequently prescribed. However, both have received black-box warnings from the US Food and Drug Administration (FDA), meaning that the market has a high level of unmet need.

Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries.

Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature.


- The current hepatitis B market contains mainly nucleoside analog reverse transcriptase inhibitors, nucleotide analogs, and interferons.

- Will these drugs continue to dominate hepatitis B treatment?

- With 81 active pipeline molecules, most of the investigational drug candidates are small molecules and vaccines, comprising 64% of the pipeline.

- What are the most prominent small molecules and vaccines in the pipeline?

- Do the pipeline molecules offer advantages over commercially proven mechanisms?

- Analysis of clinical trials since 2006 has identified a high rate of attrition in hepatitis B products.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?

- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?

- Over the 2014-2021 forecast period, the hepatitis B market in the eight major markets is expected to increase in value at a CAGR of 2.3% from $2.9 billion to $3.5 billion.

- Which markets make the most significant contribution to the current market size?

- What are the epidemiology trends in these markets?

- Which factors will influence growth rates in the different major markets?

- Despite generic sales erosion resulting from patent expirations, the uptake of premium therapies tenofovir and entecavir will contribute to significant market growth over the forecast period.

- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

- Which patent expirations will have the most significant impact on the market?

Companies Mentioned

- Chiva

- Dynavax

- Ligand

- Merck

- NeuroVive

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets